NNNN:NASDAQAnbio Biotechnology Analysis
Data as of 2026-04-20 - not real-time
$27.15
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: The stock trades at $27.15, comfortably above the 20‑day SMA ($25.83) and the 50‑day SMA ($24.56), while still below the 200‑day SMA ($32.58), indicating short‑term bullish momentum but longer‑term neutrality. The MACD line sits above its signal ($1.08 vs $0.88) and the histogram is positive, reinforcing a bullish bias, while the RSI at 56 suggests the price is not overbought.
Fundamental snapshot: Revenue surged 74% YoY to $8.65 M with exceptional margins (gross 87%, operating 59%, profit 74%), yet operating cash flow and free cash flow are deeply negative, flagging cash‑burn concerns. The trailing P/E of 181 dwarfs the industry average of 26, and the price‑to‑book of 39.5 underscores extreme overvaluation. Volatility is high at 62% over 30 days, though beta is modest (0.58), and the Fear & Greed Index reads “Extreme Greed,” hinting at speculative sentiment.
Fundamental snapshot: Revenue surged 74% YoY to $8.65 M with exceptional margins (gross 87%, operating 59%, profit 74%), yet operating cash flow and free cash flow are deeply negative, flagging cash‑burn concerns. The trailing P/E of 181 dwarfs the industry average of 26, and the price‑to‑book of 39.5 underscores extreme overvaluation. Volatility is high at 62% over 30 days, though beta is modest (0.58), and the Fear & Greed Index reads “Extreme Greed,” hinting at speculative sentiment.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and price above short‑term moving averages
- High volatility and extreme market greed signal caution
- Support level (~$20.64) provides downside cushion
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Revenue growth remains strong but cash‑burn persists
- Valuation metrics (P/E 181, P/B 39) suggest limited upside
- Neutral trend direction with price still below 200‑day SMA
Long Term
> 3 yearsNeutral
Model confidence: 4/10
Key Factors
- Sustained high margins could eventually translate to profitability
- Regulatory and geographic exposure in biotech adds uncertainty
- Current overvaluation makes long‑run price appreciation unlikely without cash‑flow turnaround
Key Metrics & Analysis
Financial Health
Revenue Growth73.90%
Profit Margin74.06%
P/E Ratio181.0
ROE27.05%
ROA14.66%
P/B Ratio39.5
Op. Cash Flow$-6739075
Free Cash Flow$-9605703
Industry P/E26.2
Technical Analysis
TrendNeutral
RSI56.5
Support$20.64
Resistance$29.95
MA 20$25.83
MA 50$24.56
MA 200$32.58
MACDBullish
VolumeStable
Fear & Greed Index87.57
Valuation
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.58
Volatility62.32%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.